Blood Gene Expression Profiling and Donor-derived Cell-free DNA to Noninvasively Diagnose Clinical and Subclinical Kidney Transplant Rejection: A Real-life Appraisal Study
Authors:
- 18 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (6) , 1026-1037
Abstract
Background.: Peripheral blood biomarkers aim to noninvasively diagnose kidney allograft rejection, but most lack robust independent validation. TruGraf is intended to exclude subclinical cellular rejection (TCMR), whereas donor-derived cell-free DNA Viracor-TRAC has proven value in excluding antibody-mediated rejection (AMR). We aim to validate both biomarkers for accurate rejection diagnosis in a real-world clinical setting. Methods.: We prospectively included 230 unselected, consecutive kidney transplants from 6 centers undergoing for-cause and protocol biopsies with paired blood samples from December 2021 to 2022. TruGraf and Viracor-TRAC were blindly run by a central laboratory. Results.: The incidence of rejection was 22.6% (17.3% surveillance; 27% for-cause biopsies). Inflammation was associated with higher TRAC levels, with AMR/mixed and microvascular inflammation (MVI) showing the highest levels (P < 0.05). TruGraf did not associate with any specific allograft injury. No biomarkers, individually or combined, accurately diagnosed any rejection (area under the receiver operating characteristic curve [AUROC] < 0.65). However, high TRAC levels, when combined with DSA in for-cause biopsies, predicted AMR/mixed rejection or MVI (AUROC = 0.817; P < 0.001), outperforming serum creatinine and DSA (AUROC < 0.65). Conclusions.: In this large, prospective, observational real-life study, we were unable to validate TruGraf and TRAC to diagnose rejection but found a useful context of use for TRAC to noninvasively diagnose AMR/mixed or MVI in conjunction with DSA in dysfunctioning graft.Keywords
This publication has 36 references indexed in Scilit:
- Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejectionAmerican Journal of Transplantation, 2023
- OPTN/SRTR 2021 Annual Data Report: KidneyAmerican Journal of Transplantation, 2023
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Peripheral Blood RNA Sequencing Unravels a Differential Signature of Coding and Noncoding Genes by Types of Kidney Allograft RejectionKidney International Reports, 2020
- Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implicationsKidney International, 2020
- How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection?Kidney International Reports, 2019
- Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical PracticeTransplantation Proceedings, 2019
- Monitoring alloimmune response in kidney transplantationJournal Of Nephrology, 2016
- The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donorsKidney International, 2014
- Rejection of the Kidney AllograftNew England Journal of Medicine, 2010